ArticleJournal of Crohn's & colitis2026
Mapping adaptive immune responses toward fungal antigens in inflammatory bowel disease using T cell repertoire sequencing and phage-immunoprecipitation sequencing.
Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- T cell receptor clonotypes predict human leukocyte antigen allele carriage and antigen exposure history.Communications biology · 2026Article
- High throughput profiling of the B cell repertoire identifies systematic changes in the repertoire of individuals with Crohn's disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsImmune reactivity to the gut mycobiome has been implicated in inflammatory bowel disease (IBD), particularly Crohn's disease (CD), but the systemic adaptive immune repertoire targeting the gut mycobiome remains incompletely defined. We aimed to map systemic T cell and antibody responses to fungal antigens in IBD.
methodsWe quantified expansion of fungal-specific T cell receptor β (TRB) clonotypes in the SPARC IBD cohort (CD, n = 1890; ulcerative colitis [UC], n = 914). In participants with paired data (n = 637), we analyzed the gut mycobiome by ITS2 sequencing and linked prevalent amplicon sequence variants (ASVs) to TRB clonotypes using a co-occurrence framework. For humoral immune profiling, we built a Saccharomyces cerevisiae-focused PhIP-Seq library and screened sera from CD (n = 100) and healthy controls (n = 60), including anti-S. cerevisiae antibody+ (ASCA+) and ASCA- individuals.
resultsFungal-specific TRB clonotypes showed greater expansion in CD than UC, including increased responses toward S. cerevisiae and enrichment in more aggressive CD phenotypes. Co-occurrence analysis identified a limited number of TRB-mycobiota associations, consistent with the largely private nature of the gut mycobiome at the ASV level. Antibody reactivity to S. cerevisiae peptides was low relative to common viral and bacterial antigen classes, and no single S. cerevisiae peptide was associated with anti-S. cerevisiae antibody serostatus.
conclusionsCD is associated with expansion of fungal-specific T cell clonotypes, but S. cerevisiae peptide-based PhIP-Seq reveals limited shared IgG reactivity. Broader antigen libraries and complementary assays capturing glycosylated and virulence-associated fungal epitopes will be needed to comprehensively define antifungal humoral immunity in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.